Browse Articles
Discover research articles across all indexed journals
The effectiveness of orthodontic treatment with clear aligners in different thicknesses
Bending stiffness of Toxoplasma gondii actin filaments
Impact of neoadjuvant radiation therapy modalities on post-surgical lymphopenia in operable pancreatic cancer.
710 Background: Recent advances in therapeutic vaccines show promise for KRAS -mutated pancreatic cancer (PC), with ongoing clinical trials exploring their potential further. Lymphocytes are essential in generating vaccine-induced immune response. Patients who develop lymphopenia following neoadjuvant radiation therapy (RT) are frequently excluded from these vaccine trials. We aimed to assess how different modalities of neoadjuvant RT impact the severity and incidence of lymphopenia. Methods: We identified patients with PC who received neoadjuvant therapy including RT followed by surgery at our institution between March 2009 and June 2024. Patients were stratified by the type of RT they received: conventional long-course chemo-RT (LCRT) with 50.4 Gy over 28 fractions (Fr), short-course chemo-RT (SCRT) with 36 Gy over 15 Fr, and stereotactic body RT (SBRT) with 30 Gy over 5 Fr. The absolute lymphocyte count (ALC, 10 3 cells/µL) was compared at various timepoints: baseline, during RT, 6-weeks after surgery (post-op), and every 3-month interval up to 1 year post-op. Moderate lymphopenia was defined as ALC <1.0 and severe lymphopenia as ALC <0.5. Results: Among the 627 patients included in the study, 522 had baseline pre-RT ALC data available for analysis. There was no difference in baseline ALC among the different RT groups (Table). During RT, patients receiving LCRT experienced a higher incidence of severe lymphopenia (86.1%; median ALC (mALC) nadir 0.28) compared to SCRT (41.9%; mALC nadir 0.50) or SBRT (20.0%; mALC nadir 0.72, p<0001). No difference in the mALC or rates of lymphopenia was observed beyond 6 weeks post-op. Notably, 53% of the patients experienced lymphopenia for as long as 1 year after surgery. Conclusions: LCRT resulted in more severe lymphopenia compared to SCRT or SBRT during RT, but this difference in severity diminished 6 weeks after surgery. Alternatives in treatment sequencing for operable pancreatic cancer can have profound effects on patterns of disease recurrence. When applying multiple treatments in series, toxicities such as lymphopenia may impact receipt of therapy. Techniques to mitigate such toxicities, while maximizing response, will be important to consider. Absolute lymphocyte count (ALC, 10 3 cells/µL) at different time point. Patients with baseline ALC LCRT (n=454) SCRT (n=34) SBRT (n=34) P-value Baseline ALC, median (IQR) 1.48 (0.74) 1.27 (0.94) 1.51 (0.74) 0.74 6-week lymphopenia, n (%) No Moderate Severe 173 (37)219 (46)79 (17) 13/27 (48)11/27 (41)3/27 (11) 18/35 (51)16/35 (46)1/35 (3) 0.10 1-year lymphopenia, n (%) No Moderate Severe 101/217 (47)90/217 (41)26/217 (12) 3/8 (37)5/8 (63)0/8 (0) 9/13 (69)1/13 (8)3/13 (23) 0.054
A prospective multi-site translational study investigating the association of gut microbiome (GM) diversity with pathological complete response (pCR) after neoadjuvant treatment in early stage rectal and esophageal cancer.
TPS849 Background: The diversity of the GM is defined as the number and relative abundance distribution of distinct types of microorganisms colonizing within the gut. Studies have suggested that dysbiosis of the GM confers a predisposition to certain malignancies and impacts response to immunomodulating therapies. The influence of the GM diversity on the pathological response after neoadjuvant chemotherapy and radiotherapy is unclear. Some studies have suggested that the GM may offer predictive biomarkers for response to chemoradiation in rectal cancer. Other studies in early-stage rectal cancer patients indicated an association between GM diversity and pathological outcomes following neo-adjuvant therapy (NAT). We hypothesize that a more diverse GM constitution at baseline leads to an improved pathological response at the time of definitive surgery. Methods: We designed a cross-institutional translational study investigating the impact of the GM diversity on the efficacy of NAT in GI cancers by assessing its association with pathological response. The study population includes patients with early-stage rectal or esophageal cancer due to commence NAT (including chemotherapy and chemoradiation) who are planned for definitive surgery. Exclusion criteria includes prior allogenic tissue/solid organ transplantation and prior receipt of anti-cancer therapy. The study assessments include fecal sampling of the GM prior to NAT, upon completion and again six months post completion of therapy. Fecal samples are analysed by 16S RNA sequencing. Pathological response will be examined at time of surgery and patients will be classified as responders (complete pathological response) or non-responders. The primary endpoint of the study is to examine the association between the GM diversity and pathological response. Exploratory analysis will include the assessment of the association between cf-DNA and the GM diversity as well as an assessment of the association between cf-DNA at baseline and pCR. Species richness (Alpha Diversity) will be analysed using the Shannon diversity index and Jaccard similarity index will be used to calculate beta diversity. Following planned study recruitment, classification and clustering analysis will be performed with Principal Component Analysis (PCA) and Random Forest analysis. Logistic regression analysis adjusting for potential confounding factors will be employed to assess the primary endpoint of the association between GM and complete pCR in the final statistical analysis. Adjusted odds ratios (OR) and 95% confidence intervals will be presented. This trial accrued 11 patients between May 2023 and Sept 2024. Out of the 11 patients enrolled, 9 patients have undergone their planned surgery. We are expecting to have 30 patients accrued prior to Jan 2025.
A retrospective study of colorectal cancer CT imaging features involving microsatellite instability.
265 Background: This study aimed to identify correlations between CT imaging characteristics accessible to the radiologist with microsatellite instability (MSI) status among colorectal cancer. Noninvasive identification of MSI status can decrease time to treatment if pathology can be bypassed. Methods: 109 colorectal cancer patients were identified retrospectively from 2011 to 2018 with an average age of 61 years (58 male, 51 female) and had MSI pathological assessment. These subjects all had CT abdomen and pelvis obtained at the time of initial diagnosis. Imaging features of both the primary and metastatic lesions were assessed. Primary lesion features included: location, size, stage, attenuation compared to the liver, growth pattern, tumor margin, primary mass area, and the presence/absence of mesenteric infiltration. Metastatic lesion features included: size, attenuation relative to liver, and enhancement pattern. Patient age, sex, and tumor staging were obtained from patient medical records. Statistical analysis was performed using various methods, including chi-square, Mann-Whitney and Kruskal-Wallis tests. Results: 5 tumor characteristics displayed a statistically significant relationship with MSI status. MSI-H lesions were more likely to be clinical Stage 2, and MSI-L lesions were more likely to be Clinical Stage 3 (p=0.012). Tumors with distant metastasis were more likely MSI-L versus regional metastasis were more likely MSI-H (p<0.001). Primary mass area was larger in the MSI-H than MSI-L group (p<0.001). Tumors in the left colon are more likely to be MSI-L versus CRC tumors in the right colon are more likely to be MSI-H (p<0.001). MSI-H tumors had a lower primary tumor Hounsfield Unit standard deviation (SD) than MSI-L tumors (p=0.002). The remaining features were not statistically significant. For primary lesion, these include mesenteric infiltration (p=0.189), tumor margin (p=1.000), enhancement pattern (p=0.498), growth pattern (p=0.127), tumor CT density (p=0.162), and liver density (p=0.105). Enhancement of metastasis also had no difference (p=0.376). Conclusions: Multiple CT imaging characteristics were predictive of MSI classification in CRC tumors, holding potential clinical relevance that can help guide individualized therapy. While these results were statistically significant, more research must be done to validate these findings and to derive useful nomograms.
Adherence to the multi-target stool DNA test in the US Hispanic population from 2016-2024.
100 Background: With colorectal cancer (CRC) as the second most common cause of cancer-related mortality in the US, adherence to CRC screening is a vital component to alleviating the cancer burden. Statistics show that only 52% of Hispanic or Latino individuals ≥45 years were up-to-date with CRC screening in 2021. A guideline-recommended, at-home CRC screening option, such as the multi-target stool DNA test (mt-sDNA), could be an efficient modality for screening average-risk individuals. Using a large national claims database, we examined CRC screening adherence with mt-sDNA in the US Hispanic population. Methods: Data was sourced from a database of over 165 million individuals linked with Exact Sciences Laboratories data. Hispanic persons who received mt-sDNA orders and resided in the US were retrospectively identified from 2016 to 2024. The analyses included persons who were ≥45 years of age, new to mt-sDNA and average risk for CRC during the 12-month pre-index period. Primary outcome of interest was adherence, which was defined as the mt-sDNA kit return rate within 365-days from shipment. All patients received a mailed letter along with digital outreach through the accompanying patient navigation program, according to their communication preference. The modes of digital outreach included: SMS, email, or both. Baseline demographics collected included age, sex, ordering provider, residential geography, payor, and outreach preference. Adjusted analyses were used to examine effects of covariates on adherence. Results: A total of 447,968 mt-sDNA orders were shipped during the study period and the overall adherence rate was 62.5%. Average time to test return was 28.5 days. Women comprised the majority of the cohort (59.9%), resided mostly in the Southern US (46.9%), aged 50-64 (60.9%), resided in a metropolitan area (91.2%), and received their mt-sDNA order from their primary care provider (62.7%). Across evaluated age groups, adherence was above 60% for all: ages 45-49 [60.5%]; 50-64 [62.6%], 65-75 [62.6%]), and ≥ 76 years [66.8]. By payor, Medicare-insured patients demonstrated the highest adherence (65.5%). Digital SMS was the preferred contact method (51.2%), and those opting for SMS + Email had the highest adherence rate (64.2%). Of provider specialties, individuals having their tests ordered by GIs produced the shortest time to adherence (23.2 days). Regression analyses revealed that older age (≥ 76 years), living in a rural area, and receiving fully or partially digital outreach were associated with increased mt-sDNA adherence. Conclusions: This large, national analysis reveals high mt-sDNA adherence amongst Hispanic individuals in the US, despite reports of low national CRC screening rates in this population. These data support the important role of mt-sDNA in facilitating screening engagement, while emphasizing the importance of preference-based navigation in facilitating screening test completion.
Harnessing the biology of regulatory T cells to treat disease
Insights into neuromyelitis optica spectrum disorder and pregnancy from a single-center study in Thailand
CBX2 promotes cervical cancer cell proliferation and resistance to DNA-damaging treatment via maintaining cancer stemness
Trends and disparities in palliative care utilization among patients with anal cancer: A ten-year retrospective study.
2 Background: Anal cancer patients often experience high symptom burden and psychosocial distress. Early integration of palliative care (PC) in their management can improve health-related quality of life. We examined the trends and predictors of PC utilization among hospitalized anal cancer patients in the US. Methods: A retrospective longitudinal study using the NIS database (2010-2019) was conducted. Using joinpoint regression and multivariable logistic regression, trends and factors associated with PC receipt were assessed. Results: The overall prevalence of PC utilization in the cohort of about 70,000 admissions with anal cancer was 6.9%. PC consultations increased from 3,372 to 11,081 per 100,000 anal cancer hospitalization (p-trend <0.001) with an average annual percentage change of 12.8%. Individuals ≥ 60 years with anal cancer had lower odds (Adjusted odds ratio (AOR): 0.81; 95% CI: 0.68-0.97) of receiving PC compared to their counterparts < 60 years. Patients in the second (AOR: 1.31; 95% CI: 1.05-1.62), and fourth (AOR: 1.29; 95% CI: 1.01–1.64) median household national income quartiles had about 30% greater likelihood of utilizing PC relative to those in the first income quartile. Patients in teaching hospitals had 40% higher likelihood (AOR: 1.40; 95% CI: 1.14-1.71) of PC in comparison to patients in non-teaching hospitals. Relative to patients who had a routine discharge home or with self-care, those discharged to facilities or with home health care were five-fold more likely (AOR: 5.04; 95% CI: 4.09-6.20) to receive PC. Those who died during hospitalization were also more likely to utilize PC (AOR: 33.9; 95% CI: 24.9-46.1). Other factors associated with PC receipt were non-elective admissions and higher Comorbidity burden. Conclusions: Though the trends in PC utilization have improved over the years, it remains suboptimal. Older patients were less likely to receive PC. Targeted interventions are needed to narrow the identified disparities for optimal utilization of PC in this patient population. Factors predicting the use of palliative care among hospitalized anal cancer patients. a Unadjusted Odds Ratio (95% CI) Adjusted Odds Ratio (95% CI) Age “60 years and above “vs “Less than 60” 0.98 (0.86-1.12) 0.81 (0.68-0.97) Hospital region South vs Northeast 1.04 (0.84-1.29) 1.33 (1.04-1.69) West vs Northeast 1.28 (1.02-1.61) 1.39 (1.06-1.82) Hospital Teaching Status Teaching vs Nonteaching 1.36 (1.16-1.60) 1.40 (1.14-1.71) Patient disposition Transfer to facility/home health care vs Routine discharge 4.98 (4.14-5.99) 5.04 (4.09-6.20) Died vs Routine discharge 39.4 (30.2-51.4) 33.9 (24.9-46.1) Admission type Non-elective vs Elective 2.97 (2.39-3.68) 2.91 (2.28-3.70) Median Household income national quartiles Quartile 2 vs Quartile 1 1.07 (0.90-1.29) 1.31 (1.05-1.62) Quartile 4 vs Quartile 1 1.17 (0.96-1.42) 1.29 (1.01-1.64) a CI = confidence intervals.
Clinical outcome of radiofrequency ablation in elderly hepatocellular carcinoma patients over 80 years old.
603 Background: The SURF trial showed the efficacy and safety of radiofrequency ablation(RFA). However, patients over 80 years old were excluded from the study. Aims: To evaluate clinical outcomes of RFA for largest hepatocellular carcinoma (HCC) diameter ≤3 cm, and ≤3 HCC nodules in patients over 80 years. Methods: Patients who underwent RFA at our institution for initial treatment of largest HCC diameter ≤3 cm, and ≤3 HCC nodules from January 2011 to December 2023. Treatment outcome and prognosis were examined in the elderly group for cases 80 years or older and in the non-elderly group for cases under 80 years. The Cox proportional hazards model was used to analyze the factors associated with treatment outcome and prognosis. Results: Of the 518 eligible patients, 136 patients were 80 years or older. Median overall Survival (OS) was 80 (95%CI 60-96) vs. 123 (95%CI 101-NA) months (p=0.021) in the elderly vs. nonelderly group. The median recurrence-free survival was 16 (95%CI 14-22) vs. 26 (95%CI 19-30) months (p=0.023), better in the non-elderly group, Interestingly, for liver disease-related deaths, median OS was 97 (95% CI 80-NA) vs. NR (95% CI NA-NA) months (p=0.62) in the elderly vs. non-elderly group. In the multivariate analysis, factors associated with OS were ALBI grade 2 or 3 (HR 1.67, 95%CI 1.07-2.60), DCP ≥ 40mAU/ml (HR 2.08, 95%CI 1.42-3.05), persistent HCV infection (HCV non-SVR) (HR 5.45, 95%CI 3.07-9.67), nonviral liver disease (HR 4.18, 95%CI 2.31-7.55). HCC recurrence was significantly associated with male (HR 1.51, 95%CI 1.18-1.94), elderly group (HR 1.46,95%CI 1.10-1.95), PT ≥80% (HR 0.69, 95%CI 0.53-0.91), DCP ≥40mAU/ml (HR 1.37, 95%CI 1.07-1.76), and HCV non-SVR (HR 1.73, 95%CI 1.35-2.21). The factors associated with liver disease-related death were ALBI grade 2 or 3 (HR 2.16, 95% CI 1.25-3.73), DCP ≥ 40mAU/ml (HR 2.34, 95% CI 1.48-3.70) and HCV non-SVR (HR 2.22, 95% CI 1.39-3.56). Conclusions: In RFA for diameter ≤3 cm, and ≤3 HCC nodules, over 80 years was not a significant factor associated with OS or liver disease-related death. The results support that RFA would be a promising treatment option for HCC patients over 80 years.
End-of-life (EOL) outcomes and healthcare utilization for patients with hepatocellular carcinoma (HCC) who received immune checkpoint inhibition (ICI).
560 Background: ICI is standard of care treatment for advanced HCC. EOL outcomes for patients with HCC who receive ICI prior to death are unknown. We examine relationships between EOL outcomes, healthcare utilization, and receipt of ICI for patients with advanced HCC referred to our tertiary center. Methods: Patients with advanced HCC evaluated at our center on or after January 1, 2020 and who died by March 29, 2024 were included. Patients were identified using diagnostic codes for liver cancer and HCC, and subsequently verified by manual review of the electronic health record. Demographic data, Child-Pugh (CP) status, and treatment history were collected. Primary EOL outcomes include: documentation of advance directives and goals of care (GOC) conversations, location of death, palliative care referral, hospice referral, days in hospice, and code status. Secondary healthcare utilization outcomes include: systemic therapy receipt, emergency department (ED) visits, hospitalization, and intensive care unit (ICU) admissions within 14, 30, and 90 days of death. Outcomes were stratified by ICI or non-ICI as last therapy received and p-values were derived using Pearson’s chi-square test for equality of proportions. Results: Of 221 evaluated patients, 71 died and met criteria for analysis. Baseline characteristics include mean age 64.1 years, 70.8% male, 71.8% received systemic treatment (median 1 line, range [1-7]), 54.1% CPA, 37.5% CPB, and 8.3% CPC at the time of last treatment. No statistically significant differences in primary EOL outcomes were detected when stratified by receipt of ICI or non-ICI as last therapy. Median days enrolled in hospice were not statistically significant between groups (24.5 days [non-ICI] vs 10 days [ICI]; p = 0.39). A higher proportion of patients who received ICI as last therapy had increased healthcare utilization across all outcomes (see Table). Conclusions: Patients with advanced HCC receiving ICI as their last treatment before death compared to those receiving non-ICI had similar EOL outcomes but higher healthcare utilization. This may be due to increased real-world use of ICI in CPB patients. Further investigation into risk stratification to predict high healthcare utilizers could guide decision-making and conversations around ongoing use of ICI, particularly near the EOL. Healthcare utilization outcomes stratified by receipt of ICI. Outcome Before Death n = 71 90 days 30 days 14 days Therapy within Total: Last therapy ICI 33/71 (46.5%)69.7% 18/71 (25.4%)66.7% 6/71 (8.5%)33.3% ED visit Total: Last therapy ICI 29/71 (40.8%)58.6% 27/71 (38.0%)55.6% 22/71 (30.1%)59.1% Hospitalization Total: Last therapy ICI 32/71 (45.1%)59.4% 30/71 (42.3%)56.6% 29/71 (40.8%)58.6% ICU admission Total: Last therapy ICI 6/71 (8.5%)66.7% 6/71 (8.5%)66.7% 6/71 (8.5%)66.7%
Association of social deprivation and colon cancer mortality: A population-based analysis.
25 Background: Colon cancer mortality is largely influenced by social factors, with higher rates seen in deprived areas. The Social Deprivation Index (SDI) measures factors like poverty, education, and unemployment, which have been linked to poor health outcomes. This study examines the relationship between county level social deprivation and colon cancer mortality in Texas. Methods: We conducted a population-based cohort study of colon cancer deaths in Texas. We queried the National Cancer Institute Surveillance, Epidemiology and End Results Program for county level colon cancer deaths in Texas over the most recent available year, 2021. We calculated age-adjusted mortality rates (AAMRs) per 100,000 population using the direct standardization method based on the age group weights from the 2000 standard US population. Confidence intervals for AAMR were derived by estimating the standard error as the AAMR divided by square root of number of mortalities. The SDI by county was linked to mortality rate using Federal Information Processing Standards (FIPS) codes. The significance of the difference between two AAMR was evaluated by determining if the intersection of 95% confidence intervals was empty. The association between SDI and AAMR was tested using both unweighted and weighted Spearman correlation with county population as weight. Results are reported and Spearman correlation and 95% confidence interval (ρ [95% CI]). Sensitivity analysis was performed by considering only the individual components of the SDI. Subgroup analyses included age group, sex, urban counties, rural counties, and race/ethnicity groups. Results: A total of 3,800 colon cancer mortalities were identified in 2023. The statewide AAMR was 12.5 (95% CI 12.1 to 12.9). Out of 254 counties, 29 (11.4%) had an SDI ≤ 25, 61 (24.0%) had 26 ≤ SDI ≤ 50, 87 (34.3%) had SDI 51 ≤ SDI ≤ 75, and 77 (30.3%) had 76 ≤ SDI ≤ 100. Total population in counties with SDI ≥ 76 was 15,106,726 (51.1%) with AAMR 12.959 (12.379 to 13.538). In contrast, the population in counties with SDI ≤ 25 was 4,771,473 (16.1%) with significantly lower mortality (AAMR 9.752 [95% CI 8.879 to 10.625]). The population weighted Spearman correlation between county level SDI and AAMR was positive (ρ = 0.339 [95% CI 0.209 – 0.514]). The unweighted Spearman correlation between county level SDI and AAMR was also positive (ρ = 0.178 [95% CI 0.089 – 0.238]). Households with no vehicle, poverty, and unemployment were most correlated with AAMR while renter occupied housing had no association. The correlation of county level SDI and AAMR were similar for rural counties, urban counties, males, females, Whites, Hispanics and Blacks. Conclusions: This study reveals a significant positive correlation between higher SDI and increased colon cancer mortality at the county level in Texas. The findings highlight the need for targeted public health interventions in deprived areas to reduce mortality and address disparities.
Migratory behaviour of humpback whales in the southeastern Pacific under climate change
Replisomal coupling between the α-pol III core and the τ-subunit of the clamp loader complex (CLC) are essential for genomic integrity in Escherichia coli
Leading the way: How leading Chinese institutions drive MDT excellence in hepatocellular carcinoma.
563 Background: HCC MDTs involve specialists collaborating on patient cases to create personalized treatment plans. Implementing MDTs can be challenging in countries with limited resources and high disease burdens. In China, there were 368,000 new liver cancer cases in 2022 representative of 40% of global cases. Therefore, evaluating MDT practices at leading hospitals in China may offer valuable insights that could help improve HCC MDT practices worldwide. Methods: This study selected hospitals with distinct MDT models: one for all new patients and one for complex cases. Hospitals handling over 1,000 HCC cases annually were chosen. Desk research and virtual interviews with MDT members from three leading Chinese hospitals—The First Affiliated Hospital of USTC, The First Affiliated Hospital of SYSU, and Tongji Hospital—were conducted to analyze their MDTs and determine key best practices. Results: We identified 6 key best practice in HCC MDTs at these leading Chinese hospitals. 1) Quality Control on MDT process: Leading hospitals ensure the MDT’s efficient execution and effective outcomes. E.g., USTC established a quality control team to audit the MDT process. 2) Real-World Evidence: Leading hospitals prioritize the construction of real-world databases linked to MDT-care to inform impact on outcomes. E.g., SYSU's preliminary data shows impact of MDT care on survival rates (From 2006 to 2010, 5,627 patients who underwent radical liver cancer resection with MDT care saw their five-year survival rate reach 60%, a notable improvement over historical averages) 3) Comprehensive Teams: These hospitals typically have robust teams, involving around 10 specialties. E.g., Tongji Hospital’s MDTs involve ~10 specialties for holistic care. 4) Patient Journey Coverage: MDTs manage patients from diagnosis to rehabilitation, providing a holistic approach to patient management. 5) Guideline-based treatment decisions: They follow latest guidelines coupled with access to approved therapies to make treatment decisions 6) Training: Young physicians are invited to actively participate in MDT consultations (e.g., through case preparation and presentation, etc.). Conclusions: Evaluation of MDT practices at leading China institutes highlights key best practices that could be adopted to enhance care quality for patients with HCC. The ongoing efforts and successes of these institutions provide a model for broader adoption and standardization of MDT practices across the country.
Landscape of <i>MET</i> genomic alterations in colorectal cancer (CRC).
247 Background: MET signaling is implicated in the tumorigenesis of many solid tumors, including CRC. MET-targeted therapies are approved in non-small cell lung cancer with novel agents in clinical trials for tumors with MET exon 14 splice site mutations, MET amplifications, and recently MET expression. There is emerging therapeutic interest in targeting MET in CRC. Methods: Tumor samples from 50,500 cases of clinically advanced CRC were analyzed by hybrid capture-based comprehensive genomic profiling (CGP) that evaluated all classes of genomic alterations (GA). MSI-high status, tumor mutational burden (TMB), genomic ancestry, trinucleotide mutational signatures, and homologous recombination deficiency signature (HRDsig) were assessed for patients with activating MET GA. PD-L1 expression was determined by IHC (Dako 22C3 with TPS scoring system). Results were compared using the Fisher exact test with the Benjamini-Hochberg adjustment. Results: A total of 502 (1.0%) cases of activating GA of MET (METmut) were identified, including 418 cases (0.83%) with MET amplification (METamp), 10 (<0.1%) rearrangements, and 78 (0.1%) short variant (SV) mutations with 19 (<0.1%) cases of MET exon 14 splice site mutations. When compared with MET wild-type (METwt) CRC, the METmut CRC were of similar age (median 62 years), and numerically more likely to be male (61.4% vs 56.0%; P=.05). There were no differences in genomic ancestry (72% European ancestry for both groups). The METmut CRC featured more cases with a POLE signature (3.6% vs 0.4%; P=<0.0001) and more GA per tumor (7 vs 5; P<0.0001). MSI-high status was similar in both groups, with 4.2% in METmut and 6.0% in METwt (P=0.28). TMB levels were numerically higher in the METmut cases (TMB ≥ 10 mutations/Mb at 12.2% vs 9.0%; P=0.058). Low level PD-L1 expression (1-49% TPS) was similar in both groups (13.9% in METmut vs 13.3% in METwt), and while not statistically significant, high level PD-L1 expression (>50% TPS) was higher in the METmut group (4.3% vs 1.6%; P=0.056). The frequencies of HRDsig+ CRC were rare and similar in both groups with 1.5% in METmut and 1.7% in METwt. METmut CRC had lower frequencies of GA in KRAS (34.7% vs 48.8%; P<0.0001), NRAS (1.8% vs 4.2%; P=0.011), APC (72.5% vs 78.2%; P=0.009) and PIK3CA (12.2% vs 18.9%; P=0.0004), and higher frequencies of GA in CDK6 (10.2% vs 0.6%; P<0.0001), EGFR (5.2% vs 0.2%; P=0.0002), ERBB2 (9.6% vs 5.2%; P=0.0004), HGF (8.0% vs 0.8%; P<0.0001), POLE (4.2% vs 0.5%; P=0.005) and TP53 (84.1% vs 75.9%; P<0.0001). In METmut CRC, ERBB2 alterations were 4.1% amplifications, 2.9% sequence mutations, 0.9% with more than one mutation. BRAF V600E was seen in 5.9% in METmut CRC and 8.4% of METwt. Conclusions: CGP reveals significant differences in the genomic landscapes of METmut CRC and METwt CRC, which may guide selection of potential rational drug combinations with novel MET-targeted therapies.
Nelmastobart (hSTC810) combined with capecitabine therapy in metastatic colorectal cancer with resistance or intolerance to oxaliplatin and irinotecan-based chemotherapy: A phase 1b clinical trial.
162 Background: Treatment options for patients with metastatic colorectal cancer (mCRC) who experienced disease progression after receiving oxaliplatin and irinotecan-based chemotherapy are limited. Nelmastobart (hSTC810), a humanized anti-BTN1A1 (butyrophilin subfamily 1 member A1) monoclonal antibody of the IgG4 isotype, showed acceptable safety profile and the disease control rate was 39.3% in the first-in-human study, suggesting its potential efficacy. This phase Ib study was designed to evaluate the safety and explore synergistic anti-tumor activity of nelmastobart in combination capecitabine. The study aims to determine the maximal tolerated dose (MTD) and recommended phase ll dose (RP2D) of this combination therapy in patients with mCRC who are refractory to standard therapy. Methods: Dose escalation phases were conducted in patients with mCRC who were administered orally twice daily capecitabine (850mg, 1000mg, 1250mg orally, days 1-14) and nelmastobart (400mg, 800mg intravenously every 3 weeks). Standard "3 + 3" dose escalation was used to define the MTD. In this phase 1b, 12 participants enrolled between February 5 2024 and June 11 2024 were 18 years of age or older with mCRC previously treated oxaliplatin and irinotecan in the metastatic setting. Results: The first 3 patients at the dose level 0 (nelmastobart 400mg, capecitabine 1,000 mg/m 2 twice daily) and level 1 (nelmastobart increased to 800 mg, capecitabine 1,000mg/m 2 twice daily) had no dose-limiting toxicities (DLTs). In dose level 2 (nelmastobart 400mg, capecitabine 1,250mg/m 2 twice daily), 2 of 3 had DLTs (grade 3 hand-foot syndrome), which were attributed to capecitabine. When dose level 2 was expanded to 3 additional patients, 2 more patients experienced DLTs (grade 3 mucositis and hand-foot syndrome). Consequently, the combination of nelmastobart 800 mg once every three weeks and capecitabine 1,000 mg/m² twice daily (2 weeks on 1 week off) was established as the MTD/RP2D in patients with mCRC. The most common AEs were hand-foot syndrome (n=4), nausea (n=3) and stomatitis (n=2) which were related with capecitabine. Four patients experienced grade 1 fatigue, which was considered to be related to nelmastobart. Two patients (16.7%) out of 12 showed partial response and 8 patients have maintained stable disease for more than 4 months among 9 patients who had a median follow-up of more than 4 months (as of August 30). Conclusions: The combination of hSTC810 and capecitabine is well tolerated at the MTD, without unexpected AEs and shows promising antitumor activity in patients with heavily treated mCRC. The phase 2 study is currently in progress. Clinical trial information: NCT0599054 .
Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial.
673 Background: Pamrevlumab (Pam) is a fully human recombinant monoclonal antibody against connective tissue growth factor. Early clinical data with Pam plus chemotherapy showed a favorable safety profile and potential efficacy in PDAC. In PrP, Pam + GA was tested as first line (Line 1) and second line (Line 2) therapy for mPDAC vs GA. PrP is a phase 2/3, innovative Bayesian adaptive platform trial sponsored by the Pancreatic Cancer Action Network testing multiple experimental arms efficiently against common controls (1). Methods: Randomization is 70% (adaptive amongst experimental arms in stage 1) and 15%:15% amongst two control arms (GA, mFOLFIRINOX). Pam + GA graduates from stage 1 to 2 if the Bayesian predictive power (PP) of eventual success is ≥ 35% for one of the arm’s signatures [Line 1, Line 2 or Line 1 & 2 (All)]. All participants (pts) are followed for 12 months (mos) after last pt randomized and treated in Pam + GA. Stages 1 and 2 are combined for final analysis. Efficacy is defined by overall survival (OS) hazard ratio (HR, experimental vs control), by a Bayesian statistical model. Superiority (HR < 1) is claimed at final analysis if the Bayesian probability of superiority is ≥ 98%. Results: Pam + GA entered PrP in Jun 2021. Between 6/2021 - 1/2023, at 23 US sites, 317 pts were treated and are included in the mITT analysis. 213 pts were treated in the Pam + GA arm (102 Line 1; 111 Line 2), 45 in the GA arm (23 Line 1; 22 Line 2), 31 in the mFOLFIRINOX arm and 28 in other experimental arms. All treated pts before and during Pam + GA enrollment were in the Bayesian model, with outcomes adjusted via a time machine to increase the trial’s statistical power. Baseline characteristics were balanced across the arms. Pam + GA met criteria to graduate to stage 2 in Sep 2022 in the All signature (Line 1 & 2). At final analysis, Pam + GA did not meet the OS primary endpoint [model estimated HR: 1.18 (95% credible interval, 0.88, 1.56), posterior Pr(HR < 1) = 0.14, below specified ≥ 0.98]. No benefit was seen in PFS nor ORR (Table). No new safety signals were seen. Conclusions: PrP, the first Bayesian platform trial in mPDAC, performed as designed; Pam + GA did not improve OS versus GA in Line 1 and Line 2 mPDAC. The novel Bayesian design warrants further study in mPDAC to enhance efficiency of drug development. Future designs should explore different strategies to allocate patients to control arm(s) vs experimental arms and accommodate novel agents intended to benefit subsets of mPDAC. 1. Picozzi, ASCO TPS 4188, 2022. Clinical trial information: NCT04229004 . Line 1 Line 2 GA Pam + GA Hazard Ratio GA Pam + GA Hazard Ratio Model Estimated mOS (mos) 11.3 9.7 1.18(95% CI* 0.88, 1.56) 7.8 6.6 1.18(95% CI* 0.88, 1.56) mPFS (mos) 5.3 5.9 0.64(95% CI^ 0.36, 1.14) 7.0 3.9 1.35(95% CI^ 0.78, 2.33) ORR (%) 26.1 35.3 4.5 9.0 *Credible Interval. ^Confidence Interval.
Alpha synuclein overexpression can drive microbiome dysbiosis in mice
Abstract Growing evidence indicates that persons with Parkinson disease (PD), have a unique composition of indigenous gut microbes. Given the long prodromal or pre-diagnosed period, longitudinal studies of the human and rodent gut microbiome before symptomatic onset and for the duration of the disease are currently lacking. PD is partially characterized by the accumulation of the protein α-synuclein (α-syn) into insoluble aggregates, in both the central and enteric nervous systems. As such, several experimental rodent and non-human primate models of α-syn overexpression recapitulate some of the hallmark pathophysiologies of PD. These animal models provide an opportunity to assess how the gut microbiome changes with age under disease-relevant conditions. Here, we used a transgenic mouse strain, which overexpress wild-type human α-syn to test how the gut microbiome composition responds in this model of PD pathology during aging. Using shotgun metagenomics, we find significant, age and genotype-dependent bacterial taxa whose abundance becomes altered with age. We reveal that α-syn overexpression can drive alterations to the gut microbiome composition and suggest that it limits diversity through age. Taxa that were most affected by genotype-age interaction were Lactobacillus and Bifidobacteria . In a mouse model, we showed direct link between alpha synuclein geneotype (hallmark of PD), a dysbiotic and low-diversity gut microbiome, and dysbiotic levels of Bifidobacteria and Lactobacillus (most robust features of PD microbiome). Given emerging data on the potential contributions of the gut microbiome to PD pathologies, our data provide an experimental foundation to understand how the PD-associated microbiome may arise as a trigger or co-pathology to disease.